Ebola vaccine booster study aims to strengthen protection for frontline workers

NCT ID NCT02788227

Completed Prevention Sponsor: National Institutes of Health Clinical Center (CC) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a booster dose of the Ebola vaccine (V920) could improve and extend immune protection in 248 healthy adults at risk of Ebola exposure through their jobs. Participants received the primary vaccine and were randomly assigned 18 months later to get a booster or not. Researchers measured antibody levels over 36 months to see if the booster helped.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ebola vaccine (rVSV∆G-ZEBOV-GP, V920)
What this could lead to: If successful, this could show that a booster shot strengthens and prolongs protection against Ebola for healthcare and lab workers.
What could go wrong: This is a mid-stage study with only 248 participants, so results may not apply to everyone. The vaccine's long-term effectiveness is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Health Canada, 539 John Buhler Research Center

Winnipeg, Manitoba, R3E 3P4, Canada
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
The Hope Clinic of the Emory Vaccine Center, Emory University

Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.